A few years back, the CEO of a marketing startup got fired for taking a tab of LSD before a company meeting. Not a recreational dose — a sliver, what people in certain circles call a microdose. He said it would sharpen his focus. The board said it violated company policy. The internet, predictably, lost its mind for about forty-eight hours and then moved on.

But the question underneath that story hasn't gone anywhere. Does microdosing psychedelics actually do what people claim it does? Is it a legitimate cognitive tool, a placebo with great PR, or just an expensive way to get on the wrong side of the law? If you're reading this, you've probably wondered. Maybe a friend swears by it. Maybe you've read a profile of a founder who credits LSD with their breakthrough. Maybe you're curious whether the same compounds being studied for depression and addiction might quietly help you, too.

Here's what the research actually shows, what experienced clinicians say, and why the relationship between microdosing and the deeper work of plant medicine is more interesting — and more honest — than the workplace-hack version of the story.

What Microdosing Actually Is (And Isn't)

A microdose is a sub-perceptual dose. That's the technical definition. You take roughly a tenth of what a recreational user would take — somewhere around 10 to 20 micrograms of LSD, or 0.1 to 0.3 grams of dried psilocybin mushrooms — at intervals over weeks or months. The idea is that you feel almost nothing. No visuals, no ego dissolution, no cosmic download. Just a faint shimmer underneath your normal day.

People who microdose report better mood, more creative thinking, sharper focus, an easier time meditating, and reduced anxiety. Those are the claims. The protocol most often cited — one day on, two days off — comes from psychologist James Fadiman, who's been writing about this since the 1960s. He's the godfather of the whole movement, and he's also remarkably measured about what he thinks it does.

What microdosing is not is a psychedelic experience. You don't journey on a microdose. You don't confront your shadow or meet ancestors or weep through twenty years of unprocessed grief. That's macrodose territory — heroic doses, as researchers call them — and it's a fundamentally different thing. Conflating the two is one of the more common mistakes people make when they start reading about this stuff.

Does the Science Back It Up?

Short answer: not really. Not yet, anyway, and possibly not at all in the way enthusiasts hope.

The most rigorous study to date, published a few years ago in eLife, ran a self-blinded trial where participants took either real microdoses or placebos. Both groups reported improvements in mood, energy, and cognition. The catch? The improvements were essentially identical. The active-dose group didn't outperform the placebo group in any meaningful way. The researchers' polite conclusion was that the reported benefits of microdosing appear to be largely placebo-driven.

That's not nothing. Placebos are powerful. If taking a tiny dose of something exotic makes you believe you'll be sharper and calmer, you probably will be sharper and calmer for a while, because expectation shapes experience. But you can get the same effect from a daily ritual, a multivitamin, or — if we're being honest — a decent cup of coffee.

Researchers at Johns Hopkins, who run the most established psychedelics program in the country, have been blunt: the strong evidence for psychedelics as a therapeutic tool lives almost entirely at the high-dose end. The benefits don't seem to scale down. If anything works at microdose levels, it's most likely a mild antidepressant effect from nudging the serotonin system — which is also exactly what SSRIs do, with fewer legal complications and decades more safety data.

Why Silicon Valley Fell in Love With It Anyway

The tech industry's romance with microdosing isn't really about the pharmacology. It's about the story. Steve Jobs famously called taking LSD one of the most important experiences of his life. Founders trade Fadiman's protocol like a productivity hack. The narrative goes: smart, ambitious people gain an edge by treating their brains like an OS that can be patched and optimized.

And look — the underlying impulse isn't crazy. Psychedelics genuinely do something to cognition. People who take real, meaningful doses in well-held settings often describe lasting shifts in perspective, creativity, and emotional flexibility. The mistake is assuming you can get those benefits in tenth-strength increments while still running a 10 a.m. stand-up.

You can't, mostly. The actual transformative effects of psychedelics seem to require the full experience — the discomfort, the surrender, the eight hours where you cannot, under any circumstances, lead a meeting. That's not a bug. That's the point. The deep work happens precisely because the usual self is offline.

The Legal and Practical Risks Nobody Mentions

This is the part of the conversation that gets glossed over in glowing founder profiles. LSD, psilocybin, and MDMA are Schedule I substances in the United States. Possessing them is a federal crime. Microdosing at work, the way the Iterable CEO learned, can also end your career fast — even in companies that consider themselves enlightened about substance use.

Then there are the practical issues. When you're sourcing tabs or mushrooms from someone you met through a friend of a friend, dose accuracy is a fantasy. People aim for 15 micrograms of LSD and accidentally take 80. Suddenly the wall is breathing during a budget review. Researchers have heard versions of this story more times than they care to count.

Some honest concerns to sit with if you're considering this:

• Unknown long-term effects on the heart. Chronic serotonin agonism may carry cardiac risks, particularly to heart valves. The research isn't conclusive, but it isn't reassuring either.
• Drug interactions. If you're on SSRIs, lithium, MAOIs, or several other medications, mixing in psychedelics — even small amounts — can be dangerous or counterproductive.
• Mental health history matters. A personal or family history of psychosis or bipolar disorder is a real contraindication, not a footnote.
• Legality. No retreat, no doctor, and no supportive board of directors will protect you from a federal possession charge in most U.S. states.

Where Plant Medicine Actually Fits In

If you've gotten this far, you might be sensing the more interesting question underneath all this. People aren't microdosing because they want to optimize quarterly OKRs. Most of them are quietly hoping for something deeper — relief from depression, a way out of an addiction, a softening of trauma, a sense that there's more to life than the loop they've been running for fifteen years.

That's the territory where psychedelics genuinely shine, and it's not microdose territory. Clinical trials with psilocybin for treatment-resistant depression have produced results that legitimately surprised the researchers. Ibogaine has helped people walk away from opioid dependency in ways nothing else has. Ayahuasca ceremonies, conducted in traditional contexts with experienced facilitators, have given people decades of stuck patterns to chew on in a single night. These are the master plants — substances that traditional cultures have worked with for generations, in settings designed to hold the weight of what they bring up.

The honest framing is this: a microdose is a hack. A retreat is a reckoning. They're different tools for different jobs. If what you actually want is a slightly better Tuesday, drink a coffee and go for a walk. If what you want is to look honestly at why your Tuesdays feel the way they do — that's a different conversation, and it probably involves a real dose, a real container, and people who know what they're doing.

Choosing the Slower Path

The thing about psychedelic healing — the real thing, not the productivity version — is that it works in the opposite direction from optimization. It asks you to slow down, not speed up. It rewards surrender, not control. The Silicon Valley pitch of move-fast-and-break-things is almost exactly the wrong posture for the work.

People who come out of a well-run retreat tend to describe months of integration afterward. Slow re-entry. Conversations with a therapist or guide. Changes that show up not as a sudden flash of insight but as a different relationship to their own habits over time. None of that fits in a microdose protocol. None of it shows up in a single ceremony, either — the integration is the medicine, in many ways.

If you're weighing whether this path makes sense for you, take your time. Read accounts from people who've done it. Ask hard questions about lineage, safety screening, and what happens if something difficult comes up in ceremony. The good operators welcome those questions. The sketchy ones don't.

For readers who want to explore this more seriously, a range of vetted ayahuasca, psilocybin, and other plant-medicine retreats can be browsed on our marketplace here. It's a quieter and more considered route than the workplace microdose — and, by most accounts of the people who've actually done both, a far more useful one.